SCHEMBL4702525

SCHEMBL4702525

CCOC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(OC(C)C)cc3)ccc2n1-c1ccc(OC(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
THRB P10828 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 4/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
TP53 P04637 2/20 0.38
CHRNA7 P36544 1/20 0.38
HPGD P15428 1/20 0.38
RECQL P46063 1/20 0.38
NR1H2 P55055 1/20 0.37
EPHX2 P34913 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
BCL2 P10415 1/20 0.36
MCL1 Q07820 1/20 0.36
RORC P51449 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697691 0.88 PTGES (0.48) PTGESEPHX2NR1H4KMT2ABCL2
SCHEMBL4698539 0.87 PTGES (0.41) PTGESSMN1; SMN2THRBPOLBMAPT
SCHEMBL4925311 0.85 PPARG (0.42) PTGESSMN1; SMN2THRBPOLBMAPT
SCHEMBL4700726 0.83 PTGES (0.53) PTGESSMN1; SMN2THRBPOLBMAPT
SCHEMBL3575288 0.82 PTGES (0.44) PTGESSMN1; SMN2THRBPOLBMAPT
SCHEMBL4698605 0.80 PTGES (0.50) PTGESSMN1; SMN2THRBPOLBMAPT
SCHEMBL4697794 0.80 SMN1; SMN2 (0.41) PTGESSMN1; SMN2THRBMAPTTP53
SCHEMBL3007903 0.79 PTGES (0.43) PTGESSMN1; SMN2THRBPOLBMAPT
SCHEMBL4021254 0.78 PTGES (0.59) PTGESSMN1; SMN2THRBPOLBMAPT
SCHEMBL334136 0.78 PTGES (0.53) PTGESSMN1; SMN2THRBPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778633-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2008-12-03 EP disclosed
US-20080188473-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2008-08-07 US disclosed
EP-1778633-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-05-02 EP disclosed
WO-2005123674-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188473-A1 Indoles Useful in the Treatment of Inflammation IDO1, PTGS1, PTGER1 PTGES 4/4885SMN1; SMN2 4126/4885THRB 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.